Verastem, Inc.
$6.33-$0.53 (-7.7%)
Last close · Data as of Nov 20, 2026
- Market cap
- $339.2M
- P/E
- -1.6x
- EV / EBITDA
- -1.1x
- Revenue
- $30.9M
- Net margin
- -677.6%
- ROCE
- -97.7%
Price chart
Technical chartScreen technicals →-35.5% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -32.2%
- 3M
- -7.2%
- 6M
- +53.3%
- 1Y
- -35.5%
- 5Y
- Hidden
- This period includes a one-day price step on 24 May 2024 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.
52-week range
Day change -$0.53 (-7.7%) from $6.86 to $6.33 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in VSTM, bought on each weekday since 2021.
News & filings
What Verastem filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernThe company made a net loss of 209 million US dollars in fiscal 2025.
Strengths (1)
- Revenue more than doubled in fiscal 2025.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States.
Read moreShow less
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS, which in Phase 1/2 trial entitled RAMP 203; VS-7375, and VS-7375-101 is a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers; and AVMAPKI, FAKZYNJA, CO-PACK, is an avutometinib capsules, and defactinib tablets. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
- Sector
- Healthcare
- Shares outstanding
- 77.7M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $339.2M
- P/E
- -1.6x
- P/B
- 5.9x
- EV / EBITDA
- -1.1x
- EV / Sales
- 7.2x
- P/S
- 11.0x
- 52-week high
- $10.64
- 52-week low
- $3.45
Profitability
- Operating margin
- -550.3%
- Net margin
- -677.6%
- EBITDA margin
- -671.6%
- ROE
- -366.2%
- ROCE
- -97.7%
- ROA
- -85.0%
- Asset turnover
- 0.13
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $30.9M
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 209.1%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 128.4%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 60.3%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- -$147.1M
Solvency
- Current ratio
- 3.09
- Debt / Equity
- 1.52
- Debt / Assets
- 0.35
- CFO / Net profit
- 0.66
- Cash / Market cap
- 60.4%
Where the revenue went
FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.
| Line | FY2025 |
|---|---|
| Revenue | $30.9M |
| Cost of revenue | $5.3M |
| Gross profit | $25.6M |
| Operating expenses | $195.7M |
| Research and development | $114.6M |
| Selling, general and administrative | $81.2M |
| Operating income | -$170.1M |
| Interest and other | -$39.3M |
| Pretax income | -$209.5M |
| Tax and other | $0.00 |
| Net income | -$209.5M |
Revenue and net profit
Revenue grew 209.1% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $2.6M | -$73.8M |
| FY2023 | $0.00 | -$87.4M |
| FY2024 | $10.0M | -$130.6M |
| FY2025 | $30.9M | -$209.5M |
Cash flows
FY2025: -$137.5M from operations, -$147.1M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | -$63.7M | -$63.7M |
| FY2023 | -$86.5M | -$86.5M |
| FY2024 | -$104.8M | -$104.8M |
| FY2025 | -$137.5M | -$147.1M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $30.9M+209.1%1Y
- EBITDA
- -$207.6M
- Net profit
- -$209.5M
- Cash from operations
- -$137.5M
- Free cash flow
- -$147.1M
- Revenue CAGR, 3Y
- 128.4%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $30.9M | -$207.6M | -$209.5M | -$147.1M | -366.2% | +209.1% | +60.3% |
Monthly returns
Month-by-month returns of VSTM across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $246.4M |
| Current assets | $223.4M |
| Non-current assets | $23.0M |
| Liabilities | $189.2M |
| Current liabilities | $72.3M |
| Non-current liabilities | $117.0M |
| Equity | $57.2M |
| Paid-in capital | $1.2B |
| Retained earnings | -$1.2B |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; VSTM highlighted.
P/E against peers
Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.
Not shown (no positive earnings and no EV / Sales): Atea Pharmaceuticals, Inc., Greenwich LifeSciences, Inc., Larimar Therapeutics, Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Verastem, Inc.VSTMthis company | $339.2M | -1.6x | 5.9x | -366.2% | -1.1x |
| Atea Pharmaceuticals, Inc.AVIR | $353.7M | -2.2x | 1.3x | -57.5% | -1.4x |
| Greenwich LifeSciences, Inc.GLSI | $347.1M | -22.0x | 137.0x | -623.1% | — |
| Larimar Therapeutics, Inc.LRMR | $341.8M | — | 4.4x | -212.2% | — |
| Enanta Pharmaceuticals, Inc.ENTA | $341.1M | -4.2x | 5.3x | -126.5% | -5.1x |
| Simulations Plus, Inc.SLP | $336.4M | -5.2x | 2.7x | -51.9% | 20.8x |
| 908 Devices Inc.MASS | $333.5M | 17.1x | 2.3x | 13.6% | -12.6x |
| Abeona Therapeutics Inc.ABEO | $331.7M | 4.7x | 2.1x | 44.7% | 3.5x |
| Humacyte, Inc.HUMA | $330.8M | -8.1x | 106.4x | -1313.4% | -15.5x |
| Peer median | — | -4.2x | 3.5x | -92.0% | -3.3x |
Year-to-date ROI
VSTM since 1 January, against earlier years.
Historical volatility
VSTM's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | -2805.4% |
| FY2023 | — |
| FY2024 | -1149.6% |
| FY2025 | -550.4% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $30.9M |
| Cost of revenueCost Of Revenue | $5.3M |
| Gross profitGross Profit | $25.6M |
| Operating expensesOperating Expense | $195.7M |
| Research and developmentResearch And Development | $114.6M |
| Selling, general and administrativeSelling General And Administration | $81.2M |
| Total expensesTotal Expenses | $201.0M |
| Operating incomeOperating Income | -$170.1M |
| Interest and other | |
| Pretax incomePretax Income | -$209.5M |
| TaxTax Provision | $0.00 |
| Net incomeNet Income | -$209.5M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $246.4M |
| Current assetsCurrent Assets | $223.4M |
| Non-current assetsTotal Non Current Assets | $23.0M |
| LiabilitiesTotal Liabilities Net Minority Interest | $189.2M |
| Current liabilitiesCurrent Liabilities | $72.3M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $117.0M |
| EquityTotal Equity Gross Minority Interest | $57.2M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | -$137.5M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | -$137.5M |
| Net income, continuing operationsNet Income From Continuing Operations | -$209.5M |
| Depreciation and amortisationDepreciation And Amortization | $730.0k |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $730.0k |
| Depreciation | $30.0k |
| Amortization cash flowAmortization Cash Flow | $700.0k |
| Amortization of intangiblesAmortization Of Intangibles | $700.0k |
| Stock-based compensationStock Based Compensation | $9.4M |
| Operating gains and lossesOperating Gains Losses | $29.3M |
| Gain loss on investment securitiesGain Loss On Investment Securities | $27.5M |
| Change in working capitalChange In Working Capital | $26.0M |
| Other non-cash itemsOther Non Cash Items | $6.5M |
| Investing cash flowInvesting Cash Flow | -$9.6M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$9.6M |
| Capital expenditureCapital Expenditure | -$9.6M |
| Purchase of PP&EPurchase Of PPE | $0.00 |
| Net PP&E purchases and salesNet PPE Purchase And Sale | $0.00 |
| Purchase of investmentsPurchase Of Investment | $0.00 |
| Sale of investmentsSale Of Investment | $0.00 |
| Net investment purchases and salesNet Investment Purchase And Sale | $0.00 |
| Purchase of intangiblesPurchase Of Intangibles | -$9.6M |
| Net intangibles purchases and salesNet Intangibles Purchase And Sale | -$9.6M |
| Financing cash flowFinancing Cash Flow | $263.3M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | $263.3M |
| Debt issuedIssuance Of Debt | $75.0M |
| Debt repaidRepayment Of Debt | -$42.6M |
| Net debt issuedNet Issuance Payments Of Debt | $32.4M |
| Long-term debt issuedLong Term Debt Issuance | $75.0M |
| Long-term debt repaidLong Term Debt Payments | -$42.6M |
| Net long-term debt issuedNet Long Term Debt Issuance | $32.4M |
| Shares issuedIssuance Of Capital Stock | $197.0M |
| Common stock issuedCommon Stock Issuance | $197.0M |
| Net common stock issuedNet Common Stock Issuance | $197.0M |
| Common stock repurchasedCommon Stock Payments | — |
| Share buybacksRepurchase Of Capital Stock | — |
| Stock options exercisedProceeds From Stock Option Exercised | $33.9M |
| Preferred stock issuancePreferred Stock Issuance | $0.00 |
| Net preferred stock issuanceNet Preferred Stock Issuance | $0.00 |
| Dividends paidCash Dividends Paid | — |
| Other financing chargesNet Other Financing Charges | — |
| Interest paid (financing)Interest Paid Cff | — |
| Change in cashChanges In Cash | $116.2M |
| Cash at the start of the yearBeginning Cash Position | $89.1M |
| Cash at the end of the yearEnd Cash Position | $205.2M |
| Free cash flowFree Cash Flow | -$147.1M |
| Supplemental |
Learn while you research
Academy chapters picked for Verastem, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Growth Investing209% revenue growth is in the top tier, learn how to value growth.7 min read
- 03 Leverage RatiosDebt/Equity of 1.52 is elevated, understand what that means for solvency.6 min read
- 04 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 05 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 06 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read